Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Clevudine (L-FMAU; L FMAU; Levovir and Revovir) is a potent antiviral drug approved in South Korea and the Philippines for the treatment of hepatitis B (HBV) infections with EC50 0.1 μM in HepG2 2.2.15 cells as well as EBV. Numerous cell lines, such as MT2, CEM, H1, HepG2 2.2.15, and bone marrow progenitor cells, exhibit minimal cytotoxicity when exposed to clevodine exposure. In cells, clevudine is broken down into its monophosphate, then into its di- and triphosphates by cellular thymidine kinase and deoxycytidine kinase.
Targets |
RNA polymerase; DNA polymerase
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C10H13FN2O5
|
|
---|---|---|
Molecular Weight |
260.22
|
|
Exact Mass |
260.08
|
|
Elemental Analysis |
C, 46.16; H, 5.04; F, 7.30; N, 10.77; O, 30.74
|
|
CAS # |
163252-36-6
|
|
Related CAS # |
|
|
Appearance |
Solid powder
|
|
SMILES |
CC1=CN(C(=O)NC1=O)[C@@H]2[C@@H]([C@H]([C@@H](O2)CO)O)F
|
|
InChi Key |
GBBJCSTXCAQSSJ-XQXXSGGOSA-N
|
|
InChi Code |
InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1
|
|
Chemical Name |
1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.8429 mL | 19.2145 mL | 38.4290 mL | |
5 mM | 0.7686 mL | 3.8429 mL | 7.6858 mL | |
10 mM | 0.3843 mL | 1.9215 mL | 3.8429 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04891302 | Completed | Drug: Clevudine Drug: Placebo |
COVID-19 | Bukwang Pharmaceutical | March 19, 2021 | Phase 2 |
NCT01192854 | Completed | Drug: Clevudine Drug: Adefovir |
Chronic Hepatitis B | Eisai Co., Ltd. | February 2010 | Phase 3 |
NCT00558818 | Completed | Drug: Clevudine | Chronic Hepatitis B | Bukwang Pharmaceutical | June 2007 | Phase 4 |
NCT04347915 | Completed | Drug: Clevudine Drug: Placebo |
COVID-19 | Bukwang Pharmaceutical | May 26, 2020 | Phase 2 |
NCT00558493 | Completed | Drug: Clevudine | Chronic Hepatitis B | Bukwang Pharmaceutical | November 2007 | Phase 4 |
Typical metabolism of l-FMAU and d4T in doxycycline (Dox)-induced Tet-On-TMPK RKO cells. Antimicrob Agents Chemother . 2005 May;49(5):2044-9. td> |
Relative amounts of metabolites of l-FMAU and d4T in the doxycycline-induced Tet-On-TMPK RKO cells (data are presented as the means of three independent experiments). Antimicrob Agents Chemother . 2005 May;49(5):2044-9. td> |